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Simple Summary: Tracking therapeutic cells with non-invasive imaging methods has the potential to
provide important information on the efficacy of cell therapies. In oncology, for example, monitoring
the spatial distribution of chimeric antigen receptor (CAR) T-cells or tumour-infiltrating lymphocytes
(TILs) could be used to monitor the efficiency of cellular trafficking to target sites within a patient.
This review covers different cell labelling approaches for the non-invasive detection of therapeutic
cells using positron emission tomography (PET). The potential for the clinical translation of these
approaches and first-in-human studies is examined, as well as the translational challenges involved
and how imaging can help overcome some of these challenges.
Abstract: Cell therapy is a rapidly evolving field involving a wide spectrum of therapeutic cells
for personalised medicine in cancer. In vivo imaging and tracking of cells can provide useful
information for improving the accuracy, efficacy, and safety of cell therapies. This review focuses on
radiopharmaceuticals for the non-invasive detection and tracking of therapeutic cells using positron
emission tomography (PET). A range of approaches for imaging therapeutic cells is discussed: Direct
ex vivo labelling of cells, in vivo indirect labelling of cells by utilising gene reporters, and detection of
specific antigens expressed on the target cells using antibody-based radiopharmaceuticals (immuno-
PET). This review examines the evaluation of PET imaging methods for therapeutic cell tracking in
preclinical cancer models, their role in the translation into patients, first-in-human studies, as well as
the translational challenges involved and how they can be overcome.
Keywords: cell therapy; immunotherapy; cell tracking; PET/CT; PET/MRI; direct cell labelling;
reporter genes; immuno-PET
1. Introduction
Cell therapy is a rapidly evolving field and an important tool for personalised medicine
in cancer. A wide spectrum of therapeutic cells coined as “living drugs” has been devel-
oped in recent years for the treatment of cancer, with many undergoing clinical trials,
and some now licensed for clinical use. These include tumour-infiltrating lymphocytes
(TILs), chimeric antigen receptor (CAR) T-cells, natural killer (NK) cells, dendritic cells,
macrophage-based therapies, and drug-loaded neutrophils. CAR T-cells targeting CD19
(KymriahTM and YescartaTM) are the first cell-based therapies to be approved by the United
States Food and Drug Administration (FDA) for the treatment of acute lymphoblastic
leukemia and diffuse large B-cell lymphoma, respectively. More recently, TecartusTM, a
CD20-directed CAR T-cell therapy was granted FDA approval for the treatment of adult
patients with relapsed or refractory mantle cell lymphoma [1]. Novel technologies such as
CRISPR-Cas9 gene-editing and bispecific CAR T-cell constructs have also been introduced
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in recent years to improve T-cell targeting and function within the tumour microenviron-
ment [2,3].
As only a few are approved and clinically available, cell therapies largely remain at
the research and translational phases, with safety and cost-benefit considerations repre-
senting some of the major challenges [4]. To successfully translate and clinically implement
cell therapies, a better understanding of in vivo cellular behaviour is required, including
biodistribution, tumour trafficking, tissue retention, and clearance. New tools for the opti-
misation of cell therapies are required to answer key questions, such as cellular localisation
and accumulation at the target site, dynamic biodistribution, function, and viability of
these cells over time in vivo, as well as the precise dosing, timing, and delivery of the
administered cells to desired sites within the body.
In vivo imaging and tracking of cells can provide useful information for improving the
accuracy and efficacy of cell therapies. Non-invasive imaging is ideal for the whole-body
quantification and longitudinal monitoring of cellular and molecular processes. Cells can be
labelled and tracked using a number of imaging modalities such as single-photon emission
computed tomography (SPECT), positron emission tomography (PET), magnetic resonance
imaging (MRI), and optical imaging [5]. White blood cell scintigraphy has been used for
the imaging of infection and inflammation since the 1980s [6,7]. Autologous leukocytes are
routinely labelled with lipophilic agents such as Technetium-99 m hexamethyl propylene
amine oxime ([99mTc]Tc-HMPAO), [111In]In-oxine, and [111In]In-tropolone [8,9]. Magnetic
nanoparticles and fluorine-19 perfluorocarbon labelling of cells offers the opportunity to
track cells without the use of ionising radiation but is limited by the low sensitivity of
MRI and MR spectroscopy (MRS), as well as significant concentration of contrast agents
that are required for detection [10,11]. Although cell tracking using optical imaging can
provide valuable insights on single cell behaviour and cell-cell interactions at a microscopic
level [12], the poor tissue penetrance of light and the limited spatial resolution of these
techniques at a whole-body level, has limited the clinical application of optical imaging [13].
Positron emission tomography (PET), as a non-invasive imaging tool, has been suc-
cessfully applied to tracking the spatio-temporal dynamics of administered therapeutic
cells. PET is usually combined with computed tomography (PET/CT) to allow anatomical
co-registration and attenuation correction of the detected photons for improved detection.
PET/CT is widely available in most large hospitals and by far the most frequently used
tracer is the glucose analogue [18F]-2-fluoro-2-deoxy-D-glucose ([18F]FDG), used to probe
increased tumour metabolism for image-based treatment response assessment [14,15]. PET
offers a very high sensitivity for cell tracking: Only a trace amount of the radiopharma-
ceutical in the order of picomolar concentrations is needed for detection, pharmacokinetic
modelling, and determining the biodistribution of the administered activity [16,17]. Im-
portantly, the measured PET signal on imaging is highly quantitative as individual counts
can be directly related to the actual quantity of label, and simple reproducible metrics
such as the standard uptake value (SUV), as well as tracer kinetics, can be used to provide
quantitative measures of tracer uptake [18]. Recent development in total-body PET scanner
technology to image the entire body has the potential to improve the sensitivity of detection
by up to 40-fold for the whole body, and up to 5-fold for a single organ, and therefore offers
a promising tool to quantifiably track a very small number of labelled therapeutic cells
in vivo [19]. Furthermore, the use of PET to detect and track therapeutic cells has been
facilitated by the development of new radiopharmaceuticals which offer a wide range of
potential labels for cell labelling.
A number of different approaches can be used to label and image the spatial distri-
bution of therapeutic cells in tissue: Direct labelling of cells ex vivo, indirect labelling of
cells in vivo using gene reporters, as well as the detection of specific antigens expressed on
the target cells using antibody-based radiopharmaceuticals (immuno-PET). This review
focuses on PET radiopharmaceuticals for cell labelling strategies in preclinical models of
cancer and the translation of these approaches into the clinic for therapeutic monitoring
in patients. The merits and limitations of each strategy are discussed and examples of
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cell tracking approaches are demonstrated, highlighting the opportunities and challenges
of clinical translation. The selection of the references was chosen to reflect a spectrum of
applications and approaches, and was not based on defined search criteria.
2. In Vivo Imaging of Directly (Ex Vivo) Labelled Cells
2.1. Non-Metal Based PET Radioisotopes with a Short Half-Life
In a direct cell labelling approach, a tracer is added to cells ex vivo followed by in-
cubation for cellular uptake of the label before labelled cells are injected into recipients.
Different strategies for cell labelling using this approach have been explored using PET
(Figure 1). Direct labelling of cells has been used for tracking the fate, biodistribution, and
migration behaviour of autologous patient-derived cells following administration into
patients using [18F]FDG ([18F], t1/2 = 109.7 min), the most frequently used and widely
available clinical PET tracer in oncology, which is transported via glucose transporters
(GLUT) and trapped intracellularly following phosphorylation by the enzyme hexokinase.
[18F]FDG has been used to track the short-term delivery of cells in patients with cancer,
inflammation, and infarction [20,21], and is more sensitive than the systemic administration
of [18F]FDG given the high background levels of [18F]FDG uptake in many organs [22].
[18F]FDG has also been used for labelling genetically engineered NK-92-scFv(FRP5)-zeta
natural killer cells in preclinical models: Higher uptake of NK-92-scFv(FRP5)-zeta cells
were seen in HER2/neu-positive tumours within a 2-h time frame compared to the parental
NK-92 cells and confirmed on autoradiography and histopathology [23]. For example,
one study injected [18F]FDG-labelled macrophage-activated killer (MAK) cells into 10 pa-
tients with peritoneal relapse of epithelial ovarian carcinoma and showed a reproducible
biodistribution pattern with trafficking to tumour sites up to 4 h following injection [24].



























Figure 1. Overview of different direct cell labelling methods: 1© Uptake mediated by cellular transporters of small molecules
(e.g., small molecules). 2© Endocytosis mediated uptake of nanoparticles. 3© Cell surface protein labelling. 4© Passive
diffusion through the lipophilic cell membrane either as an intact chelate inside the cell (A) or dissociating in the cytosol (B)
and association with intracellular proteins (C) or cell organelles (D). 5© Insertion of ligands into the lipophilic membrane.
6© Specific antigen targeting and subsequent internalisation of labelled antibody.
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The use of shorter lived radiopharmaceuticals for cell tracking is more challenging,
given the usual time taken for cells to migrate to the organ of interest. However, [11C]-
methyl iodide ([11C], t1/2 = 20.3 min) has been used for the labelling of murine natural
killer (NK) cells to measure the systemic distribution and short-term kinetics of tumour
delivery in a fibrosarcoma model in mice [25]. Differences in the tumour accumulation
between activated and non-activated cells were observed, as well as the cellular retention in
the tumour up to 1 h post-injection. Despite promising initial imaging results, the relatively
short half-lives of carbon-11 and fluorine-18, do not meet the requirements for longitudinal
tracking of directly labelled cells over several days, which is the usual timescale for cellular
migration. A general disadvantage of tracers targeting metabolic pathways is that they
are taken up and trapped within cells by active transport or enzymatic activity. Therefore,
labelling efficiency is heavily dependent on these functional processes which may vary
between cells or within cells over time.
2.2. Metal-Based and Long-Lived PET Radioisotopes
Longer-lived PET isotopes offer the potential for tracking cells over several days:
Copper-64 ([64Cu], t1/2 = 12.7 h) conjugated to nanoparticles has been investigated for the
labelling of CD19-specific CAR T-cells using both superparamagnetic iron oxide nanopar-
ticles (SPION) [26] and gold nanoparticles [27]. In a first-in-human study, CAR T-cells
specific for the carbohydrate Lewis Y antigen were labelled ex vivo with 64Cu-labelled
SPIONs, facilitated by a transfecting agent, and reinfused into patients with solid tu-
mours to investigate the distribution of labelled cells to body organs and tumour sites
within 3–5 days, using a hybrid PET/MRI approach [28]. [64Cu]Cu-pyruvaldehyde-bis(N4-
methylthiosemicarbazone) ([64Cu]Cu-PTSM), a commonly used PET perfusion tracer, has
also been used to study the biodistribution of labelled cells in healthy mice [29–31]. The
lipophilic [64Cu]Cu-PTSM passively diffuses through the cell membrane and is trapped
upon reduction inside the cell. However, the rapid cellular efflux of copper-64 has been
shown to be a problem for long term cellular retention [31–33] and imaging is only possible
for a few days [29–31]. Copper and also other metals such as manganese are essential
metabolic elements with several key cellular roles, and therefore the maintenance of home-
ostasis can lead to low intracellular retention of these radiometals, which renders the PET
isotopes of copper-64 and manganese-52 ([52Mn], t1/2 = 5.6 days) unsuitable for cellular
labelling at later time points [34].
Successful cell tracking methods for routine clinical applications require long half-life
tracers with more reliable labelling and cellular retention. Zirconium-89 ([89Zr], t1/2 = 78.4 h)
has emerged as a promising PET radioisotope for direct cell labelling and has been widely
used for antibody-based immuno-PET imaging over the last decade [35]. Analogous to
[111In]In-oxine used in SPECT imaging, zirconium-89 can be used for the synthesis of the
neutral and lipophilic complex [89Zr]Zr-oxine with four oxine (8-hydroxychinolin) ligands
bound to zirconium-89 that enters cells through the same passive mechanisms [36]. Oxine
acts as an ionophore that can transport radiometals across the cell membrane and as a
meta-stable complex dissociates to deposit the radiometal inside the cell [34]. Zirconium-89
can bind to nuclear and cytoplasmic proteins (Figure 1), is biological inert, and is ideally
suited for longitudinal cell imaging due to its residualizing properties within cells [35]. In
recent years, [89Zr]Zr-oxine has been evaluated in several in vitro and preclinical in vivo
studies for the labelling and tracking of therapeutic cells in preclinical oncology settings
which are summarised in Table 1. This approach allows the imaging of labelled cells for
at least 7 days post-injection due to the longer radioactive decay. The in vitro detection
limit of [89Zr]Zr-oxine labelled T-cells has been found to be on the order of 104 cells, with
cellular activities as low as 15 kBq/106 cells, on both clinical PET/CT and PET/MRI [37].
The clinical application of this approach is planned.
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Table 1. Preclinical cell labelling and imaging studies using 106–107 cells labelled with [89Zr]Zr-oxine.
Cell Type Purpose Cellular Activity[kBq/106]
Imaging
[Time] Reference
Dendritic cells (DCs), activated
cytotoxic T-cells (CTLs),
In vitro labelling study and in vivo
tracking of CTLs to B16-OVA
melanoma tumours
89–111 (DCs)
37 (CTLs) 7 days [38]
Mesenchymal Stem cells (MSCs)
transduced to express TNF-related
apoptosis inducing ligand (TRAIL)
In vivo tracking and biodistribution
of MSC-TRAILs to mesothelioma
tumours
311 7 days [39]
Natural killer cells In vivo tracking and biodistributionin healthy rhesus macaques 13.7 ± 5.2 7 days [40]




injected IL13Rα2 CAR T-cells to
tumour sites
70 7 days [42]
In contrast to the intracellular trapping of zirconium-89 using [89Zr]Zr-oxine, cell
surface labelling with zirconium-89 can also be achieved via chelation with the use of des-
ferrioxamine (DFO) based bifunctional chelators, such as the p-isothiocyanatobenzyl-linker
(NCS), which forms amide bonds with primary amine groups on cell surface proteins.
The stability of the [89Zr]Zr-DFO complex is of key importance since the release of free
zirconium-89 results in non-specific uptake of zirconium-89 in vivo, such as in the bones.
[89Zr]Zr-DFO-Bz-NCS has been used to label and image both CD19 targeting CAR ex-
pressing Jurkat cells and human T-cells in mouse xenograft CD19-positive models: Cells
migrated from the lung to both the liver and spleen by day 1 and were detectable until
day 7. However, no radioactive accumulation in CD19-positive tumours was observed [43].
Iodine-124 ([124I], t1/2 = 4.2 days) an organic PET isotope with one of the longest half
-lives, has been used to label CD8+ T-cells specific for the ovalbumin peptide SIINFEKL [44]:
5-124I-iodo-2′-deoxyuridine ([124I]IUdR) is an analogue of thymidine, which labels prolif-
erating cells by incorporation into DNA. Adoptively transferred 124I-labelled T-cells into
mice with bilaterally implanted melanoma tumours showed higher signal accumulation in
B16-OVA tumours expressing ovalbumin than the parental tumours (B16) on PET/MRI.
This demonstrated the specificity of T-cell tumour targeting using this approach.
There are several important considerations for direct cell labelling approaches that
need to be taken into account: The radiolabelling of cells can directly affect cellular function
secondary to chemical alterations or radiation-induced changes, and it is important that
labelled cells maintain viability and functionality post-labelling, as well as retain the radio-
label throughout the imaging time frame. Cellular efflux of the radiotracer or radioisotope
in vivo can result in uptake and retention of free tracer in other tissues and organs resulting
in non-specific background signal and therefore decreasing detectability of the injected
cells of interest. Sensitivity for cell detection can be further compromised by the dilution of
the signal from labelled cells due to cell proliferation over time, and therefore the detected
radioactivity is not necessarily proportional to the number of labelled and injected cells.
3. In Vivo Imaging of Indirectly Labelled Cells Using Reporter Genes
An additional strategy to track cells in vivo with radionuclide methods makes use
of reporter genes. These are introduced in the desired cells to express targets that can
be imaged with radiolabelled tracers after the injection of cells in vivo. This approach
allows monitoring of therapeutic cells for an extended time with repeated tracer injection
if adequate expression of the transduced gene is retained, addressing the limitations of
radionuclide half-life, activity levels to inject, and the lower long-term stability of directly
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labelled cells. Figure 2 summarises the common reporter gene approaches for tracking









e.g. NIS ([18F]TFB )
NET ([124I]MIBG, [18F]MFBG ) e.g. HSV1-tk ([18F]FEAU, [18F]FHBG )
DHFR ([18F]-TMP, [11C]-TMP)
Figure 2. Overview of gene reporters for the tracking of therapeutic cells using different PET tracers. The transfection of
cells with a vector plasmid leading to the expression of reporter genes in cells can be detected using PET imaging with
radiotracers targeting specific 1© receptors, 2© cell surface enzymes, 3© protein transporters, and 4© intracellular enzymes.
The respective PET tracer for each reporter gene discussed in the text is indicated in brackets. The figure was partly created
with BioRender.com (accessed on 7 June 2021).
Table 2. Summary of reporter genes used for the imaging of CAR T-cells in cancer.




ICAM-1 specific CAR T-cells; Jurkat T-cells 4 × 106 cells/cm3 in vivo [45,46]
tPSMAN9de [18F]DCFPyL CD19-tPSMA(N9del) CAR T-cells 2 × 103 cells in vitro [47]
NIS [18F]TFB T4NT CAR T-cells 3 × 103 cells in vitro [48]
hNET [124I]MIBG, [18F]MFBG Comparative study with transduced T-cells 3–4 × 104 cells in vivo [49]
HSV1-tk [18F]FEAU, [18F]FHBG
IL-13 zetakine CAR T-cells, CD19 CAR
T-cells, hPSMA specific CAR T-cells ~3 × 10
5 cells in vivo [50–53]
eDHFR [18F]-TMP, [11C]-TMP GD2+ CAR T-cells 4 × 106 cells/1 cm3 in vitro [54,55]
3.1. Herpes Simplex Virus Thymidine Kinase (HSV1-tk)
HSV1-tk is an intracellular enzyme with high selectivity for the thymidine analogue
ganciclovir, an inhibitor of viral DNA replication commonly prescribed to treat an HSV in-
fection [56]. Radiolabelled ganciclovir analogues in combination with HSV1-tk expression
have been utilised extensively as reporter systems for imaging [57]. The first human appli-
cation of this approach used PET imaging with 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]
guanine ([18F]FHBG) to track HSV1-tk transduced cytotoxic T-cells (CTLs) administered for
treatment of recurrent high grade glioma [50]. The concept was expanded to monitor CTL
trafficking, survival, and proliferation in seven patients with recurrent high-grade glioma
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that were resistant to conventional therapies by performing PET imaging with FHBG before
and after intracerebral CTL infusion, where a significant increase in [18F]FHBG total activity
was observed representing the CTL trafficking to tumours [51] (Figure 3). Therapeutic
concentrations of ganciclovir analogues can be used to selectively kill HSV1-tk transduced
cells. This additional feature provides a safety switch to stop the activity of the transferred
cells if desired as shown in preclinical models [58,59], and may be particularly relevant in
the regulation and control of CAR T-cells [60]. However, since HSV1-tk is a foreign protein
and potentially immunogenic, there is concern that expression of this reporter gene may
affect survival of the transduced cells once injected into patients as they may be vulnerable
to T-cell mediated killing [61].
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Somatostatin  receptor  (SSTR)  2  is  a  G‐protein‐coupled  cell  surface  receptor 
overexpressed  in  neuroendocrine  tumours  [62].  Several  high  affinity  analogues  of 
somatostatin have been developed as tracers and are routinely used for imaging SSTR2 
overexpressing  cancers  in  the  clinical  setting  [63].  The  most  commonly  utilised 
radiopharmaceutical for this purpose is the high affinity ligand [68Ga]Ga‐DOTATOC [64] 
that  has  been  explored  in  combination  with  SSTR2  for  reporter  gene  imaging  [65]. 
[68Ga]Ga‐DOTATOC  has  been  used  to  visualise  the  biodistribution  and  tumour 
infiltration of SSTR2‐expressing human T‐cells in a Jurkat cell murine tumour model [45]. 
Figure 3. Imaging of HSV1-tk gene reporter xpression in gen tically m dified CTLs with [18F]FHBG.
[18F]FHBG-PET imaging was performed in a patient with recurr nt glioblastoma multiforme tumour
in the right frontoparietal lobe before (A) and 1 week after (B) CTL infusions. Allogeneic CTLs and
IL-2 were injected intratumorally (red arrows). Tumour recurrence was monitored by T1-weighted
(T1W) MRI (top panels) and [18F]FHBG-PET images were fused with the MR images (bottom panels).
A significant increase in [18F]FHBG uptake and PET signal was detected following CTL infusion,
which was likely to be due to CTL cell trafficking. Figure reproduced from [51].
3.2. Somatostatin Receptor 2 (SSTR2)
Somatostatin receptor (SSTR) 2 is a G-protein-coupled cell surface receptor overex-
pressed in neuroendocrine tumours [62]. Several high affinity analogues of somatostatin
have been developed as tracers and are routinely used for imaging SSTR2 overexpressing
cancers in the clinical setting [63]. The most commonly utilised radiopharmaceutical for
this purpose is the high affinity ligand [68Ga]Ga-DOTATOC [64] that has been explored
in combination with SSTR2 for r porter gene imaging [65]. [68Ga]Ga-DOTATOC has been
used to visualise the biodistribution and tumour infiltration of SSTR2-expressing human
T-cells in a Jurkat cell murine tumour model [45]. The uptake of [68Ga]Ga-DOTATOC was
shown to correlate with the tumour size and percentage of SSTR2-expressing T-cells. The
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very high affinity, rapid diffusion, and clearance of SSTR2 targeting PET tracers following
injection, in addition to the location of the target on the cell surface, produces high target-
to-background binding in a rapid timescale. Clinical imaging is usually performed 1 h
after injection which provides optimal targeting [66], as opposed to the 2–3 h thus far used
for HSV1-tk-based systems [50,67]. The 18F-labelled somatostatin analogue 18F-NOTA-
octreotide (NOTAOCT) has been used to image SSTR-expressing neuroendocrine tumours
in a clinical research study [68]. It has been successfully applied to track Intracellular
Adhesion Molecule 1 (ICAM-1) targeting CAR T-cells transduced with SSTR2 with PET/CT
in mice [46]. 18F-NOTA-octreotide-PET showed specific uptake by SSTR2-transduced CAR
T-cells. The peak CAR-T cell signal was seen approximately 4 days following the peak
tumour burden and gradually decreased to background levels thereafter.
SSTR2 is a human protein and thus poses no concern for immunogenicity of trans-
duced cells. The use of this reporter system may be limited in the spleen as there is
physiological expression of SSTR2 in haematopoietic cells causing very high specific bind-
ing in this organ. The very high level of SSTR2 expression in neuroendocrine tumours
would not prevent this approach of being in these rare cancers. Since the physiological
role of SSTR2 receptors is to exert inhibition on cell proliferation when activated, their
expression in transduced cells does not pose concern for altering cell function. The activity
of transduced cells may be controlled by the use of clinically approved drugs such as
receptor agonists [69] or even with clinically approved radiolabelled drugs commonly
utilised in the treatment of advanced neuroendocrine tumours [70].
3.3. The Sodium Iodide Symporter (NIS)
The human sodium iodine symporter (hNIS) is an additional reporter gene system
that has been investigated for longitudinal cell tracking. The hNIS is physiologically
expressed in thyroid, stomach, and salivary glands and drives uptake of the diagnostic
and therapeutic radioactive isotopes of iodine and 99mTc-pertechnetate ([99mTc]TcO4−)
into these cells. These radionuclides are clinically approved and commonly used for
diagnostic studies and therapy of thyroid and salivary gland disorders. An experimental
hNIS substrate, [18F]tetrafluorborate ([18F]TFB) [71,72], has been utilised in humans to
image patients with thyroid cancer [73], as well as to image tumours and metastases in
preclinical models [74,75]. The hNIS is an excellent candidate reporter gene for human
application as it is non-immunogenic, is not internalized, and is only functional in viable
cells [71]. [18F]TFB-PET has been used for quantifying differences in NIS-transduced CAR
T-cell tumour retention in different triple-negative breast cancer models in mice with an
impressive detection limit of ~3000 hNIS expressing cells [48]. Although the physiological
uptake in normal hNIS expressing tissues is of concern, most of the background uptake
with these tracers is in the head and neck region, allowing its use in other areas of the body.
Several groups are validating this concept and clinical trials are in preparation.
3.4. Prostate Specific Membrane Antigen (PSMA)
PSMA is a cell-surface membrane glycoprotein that has been widely exploited for
prostate cancer imaging. Novel 68Ga- and 18F-labelled small molecule PET ligands have
been developed that can bind to PSMA with high selectivity and many of these are now in
routine clinical application including the very recently FDA approved, radiofluorinated
inhibitor of PSMA, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-
ureido)-pentanedioic acid ([18F]DCFPyL) [76]. Given the favourable pharmacokinetics
and the very low expression in non-target organs, this system lends itself to applica-
tions for cell tracking. Anti-CD19 CAR T-cells expressing a N-terminal modified (N9del)
PSMA, engineered to prevent internalisation and intracellular signalling which may affect
cell physiology, have been tracked in a model of acute lymphoblastic leukaemia using
[18F]DCFPyL [47]. PET imaging of CD19-tPSMA(N9del) CAR T-cells showed very high
sensitivity with a detection limit of ~2000 injected cells. Given the high sensitivity of this
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approach and the availability of therapeutic ligands of PSMA as safety switches, further
development of this approach is appealing.
3.5. Norepinephrine Transporter (NET)
NET is a transmembrane protein expressed in the central nervous system, as well as in
tumours of neural crest origin. It mediates the transport of norepinephrine, dopamine, and
epinephrine across the cell membrane [77]. Radiolabelled derivatives of norepinephrine
are clinically available for imaging phaeochromocytoma, paraganglioma, and neuroblas-
toma. Metaiodobenzyl-guanidine (MIBG) labelled with iodine-131 or iodine-123 are rou-
tinely used for imaging and therapy of advanced cancers. The development of 18F-labelled
metafluorobenzyl-guanidine ([18F]MFBG), as well as the use of 124I-metaiodobenzyl-
guanidine ([124I]MIBG), have opened up the use of PET for this approach. The hNET has
also been used as a reporter gene to image transduced T-cells in mice with [124I]MIBG and
[18F]MFBG with the latter offering the higher sensitivity in the range of 3–4 × 104 T-cells
at the site of injection [49]. However, clinical translation of this approach would require a
significantly higher tumour uptake compared to the endogenous NET expression in organs
with sympathetic innervation, which demonstrates a significant background signal [78].
3.6. E. coli Dihydrofolate Reductase (eDHFR)
More recently, an approach based on the bacterial enzyme dihydrofolate reductase
derived from E. coli (eDHFR) has been used as a reporter gene for cellular tracking. The
eDHFR can be imaged using radiolabelled versions of its ligand, i.e., a derivative of the
antibiotic trimethoprim (TMP). TMP has been labelled with carbon-11 ([11C]-TMP) [54]
and more recently with fluorine-18 ([18F]-TMP) for studying the trafficking of anti-GD2
CAR T-cells in NOD scid gamma (NSG) mouse mice bearing GD2+ human osteosarcoma
xenografts [55]. Radiolabelled TMP has the potential to achieve low background in unmodi-
fied mammalian tissues and high retention in eDHFR engineered cells. [18F]-TMP provided
high contrast imaging with a detection sensitivity of ∼11,000 cells per mm3. The eDHFR
system does not provide a readily available safety switch and requires stable expression of
a bacterial protein, which is less desirable than the expression of a human protein.
4. In Vivo Imaging of Cells Using Antibodies (Immuno-PET)
Therapeutic cells can also be imaged in vivo using radiolabelled antibodies and an-
tibody fragments. Indirect labelling of cells with antibodies provides high affinity and
specificity for the target. A number of established conjugation strategies and radiolabelling
approaches can be used for synthesising antibody-based imaging probes [79]. Cell surface
markers (such as CD3, CD4, and CD8), as well as activation or exhaustion markers (such
as OX40 and PD-1), can be detected non-invasively using radiolabelled antibodies to deter-
mine the functional status of the administered cells (Table 3). The density or number of
labelled cells at the tumour sites can be longitudinally tracked using repeated injections
overcoming the problems with signal dilution following a single injection [80].
Antibody labelling may produce functional effects on the therapeutic cells, which
require evaluation both in vitro and in vivo [79]. For example, the presence of an intact Fc
region in certain clones of antibodies has been shown to deplete target cells and this can be
overcome by engineering antibodies with cleaved Fc region or antibody fragments without
the Fc receptor [79,81]. Unmodified antibodies (~150 kDa) can exhibit slow clearance due
to the interaction with the neonatal Fc receptor and a prolonged serum half-life: Imaging at
earlier time points can be problematic due to the high background signal and non-specific
tissue accumulation. To circumvent this, enzymatic or genetic modifications of antibod-
ies have been used to engineer smaller antibody derivatives or fragments (~25–100 kDa)
such as: Monovalent F(ab’) and divalent F(ab’)2 with the antigen-binding regions linked
by disulfide bonds and no Fc portion; single-chain variable fragments (scFv); minibod-
ies; diabodies; and even smaller therapeutic proteins (<6 KDa), such as affibodies and
nanobodies [79]. Each of these antibody derivatives exhibit different pharmacokinetics
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and clearance properties. Smaller fragments with sizes below the renal filtration threshold
(<60 kDa) are generally excreted through the kidneys and have a rapid blood clearance
with minimal background signal, while full-length and larger antibody derivatives are
cleared through the hepatobiliary route. However, there is often a trade-off between max-
imum target accumulation and minimal background signal [81]. Larger molecules tend
to accumulate non-specifically in solid tumours due to the enhanced permeability and
retention (EPR) effects, as tumours tend to have irregular blood vasculature and inefficient
lymphatic drainage [82]. Therefore, when designing antibody-based radiopharmaceuticals,
it is very important to distinguish non-specific tumour uptake from true target engagement.
The choice of antibody conjugation strategy is also important when designing radio-
pharmaceuticals to detect therapeutic cells [83]. Ideally, chemical modifications should
not compromise the functionality and binding affinity of an antibody to its target, and
the reactions should occur under mild conditions to minimize protein denaturation. Bi-
functional chelators are often employed as a link between the antibody and a metal-
based radionuclide [84]. Examples include diethylenetriamine pentaacetate (DTPA),
tris(hydroxypyridinone) (THP), and desferrioxamine (DFO) that can be radiolabelled
under ambient temperature and mild acidic to neutral pH [84]. The choice of radionuclide
should ideally match the biological half-life (t1/2) of the molecules. Short-lived radionu-
clides such as Gallium-68 are suitable for scFv and diabodies with rapid blood clearance,
whilst a long-lived positron emitter such as Zirconium-89 is more suitable for detecting
therapeutic cells with full-length antibodies [85].
Imaging and detecting the presence of therapeutic T-cells in tumours has been demon-
strated using CD8 antibody fragments (Figure 4) [86–88]. For example, CD8 cys-diabodies
([89Zr]Zr-malDFO-169 cDb) engineered from rat hybridoma cell lines have been used for the
non-invasive tracking of cytotoxic T-cells in murine models of cancer immunotherapy [86].
A higher uptake of the tracer was detected in ovalbumin-expressing tumours following
adoptive transfer of CD8+ T-cells expressing the MHC Class I-restricted TCR specific for
ovalbumin (Ova) [86]. Preliminary data from a first-in-human study on six patients using
[89Zr]Zr-IAB22M2C, a radiolabelled minibody targeting CD8, demonstrated favourable
pharmacokinetics and a good safety profile [87]. Tracer uptake in CD8+ T-cell-rich tissues
such as the lymph nodes was seen as early as 2 h post-injection. Tumour uptake was
noted in two patients receiving immunotherapy (metastatic melanoma and hepatocellular
carcinoma), but not in the remaining four patients with lung metastases. The tumour
uptake of [89Zr]Zr-IAB22M2C was also histologically confirmed as CD8+ T-cell infiltration
at the periphery of a metastatic lesion in the deltoid muscle of a patient with melanoma.
The uptake of [89Zr]Zr-IAB22M2C in tumours showed areas of both concordance and
discordance with [18F]FDG-PET uptake, in addition to non-specific uptake in bone marrow
and lymph nodes. Therefore, [89Zr]Zr-IAB22M2C can be used as a complementary tracer
to [18F]FDG for the direct imaging of CD8+ T-cells.
Mall et al. developed [89Zr]Zr-Df-aTCRmu-F(ab’)2 specific for the murine T-cell
receptor (TCR) beta domain to track transgenic human T-cells engineered with murine
sequences in the TCR [89]. Differential patterns of distribution of [89Zr]Zr-aTCRmu-F(ab’)2
signals were detected in the tumours, i.e., larger tumours exhibited intense signals at the
tumour border, whilst smaller tumours demonstrated uniform distribution of signals. The
sensitivity and clinical applicability of the method was further evaluated in a separate
study [90], whereby a detection limit of 1.0 × 104 T-cells was observed when imaging was
performed on tumour-bearing NSG mice injected with different numbers of transgenic
T-cells. This observation at the preclinical level is promising and compatible with the
number of human CAR T-cells usually administered into patients for treatment in clinical
trials, which is of the order of 104 to 108 per kilogram body weight [91].
Radiolabelled antibodies can also be used for monitoring the efficacy of NK cell
therapies. A recent example is the use of radiolabelled IgG1 antibodies specific for the
human NK cell activation receptor NKp30, i.e., [64Cu]Cu-NKp30Ab to detect NK cell
trafficking in an adoptive cell transfer model [92]. A high specific uptake of the tracer was
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demonstrated in vitro on the human NK cell line NK92MI and human NK cells isolated
from buffy coats and in vivo on NKp30-expressing xenografts. The specific detection of
human NK cells residing in the liver and spleen of NSG mice following adoptive cell
transfer further demonstrated the clinical feasibility of this approach.

































Figure 4. Imaging human T-cell tumour infiltration using [89Zr]Zr-IAB22M2C, a radiolabelled
minibody targeting CD8. (A) Normal splenic, bone marrow, and lymph node uptake of the tracer
were observed. Uptake of (B) [89Zr]Zr-IAB22M2C and (C) [18F]FDG in a melanoma metastasis in the
deltoid muscle of a patient was histologically confirmed as high CD8+ T-cell infiltration (D,E). Figure
reproduced from [87].
Determining the functional status of therapeutic cells over the course of treatment is
important to ensure treatment efficacy. Radiolabelled antibodies targ ting activation and
exhaustion markers on therapeutic cells have been developed for oncological applications.
Expression of the T-cell activation marker, inducible T-cell costimulatory receptor (ICOS)
was evaluated using a full-length ICOS antibody, [89Zr]Zr-DFO-ICOS, 5 days after CD19-
specific T-cell administration in a murine model of B-cell lymphoma [93]. Although specific
uptake of the tracer seen in the bones correlated with the presence of CAR T-cells infiltrating
B-cell lymphoma in the bone marrow, using a full-length antibody for imaging ICOS was
limited as a substantial amount of non-specific uptake was observed in highly vascularized
organs such as the heart, liver, and spleen. Thus, further modification of the ICOS antibody
into more miniaturized forms may be needed to improve the pharmacokinetics of this
tracer for clinical translation.
The expression of immune checkpoint proteins on tumour-infiltrating lymphocytes
and CAR T-cells is a strong indication of immune tolerance and exhaustion, and a hallmark
of treatment failure [94]. Monitoring the expression of immune checkpoint proteins on
therapeutic T-cells and in the tumour microenvironment is important for determining long-
term treatment efficacy. Notable examples of radiopharmaceuticals that are at the stage of
preclinical and clinical testing include radiolabelled antibodies targeting the programmed
cell death 1 receptor (PD-1) [89Zr]Zr-nivolumab and [89Zr]Zr-pembrolizumab, its ligand
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PD-L1 [89Zr]Zr-atezolizumab, and [18F]F-BMS-986192, as well as the lymphocyte-activation
gene 3 (LAG-3) specific [89Zr]Zr-DFO-REGN3767 [95–98].
[89Zr]Zr-nivolumab has been investigated both in a humanised mouse model of lung
cancer [99], as well as in patients with non-small cell lung carcinoma [96]. The tracer
showed high specific binding to PD-1 expressing T-cells both in vitro and in vivo, and was
associated with T-cell infiltration in the tumours, salivary, and lacrimal glands of NSG mice
engrafted with human peripheral blood mononuclear cells [99]. In patient studies, a high
tracer accumulation was observed in the spleen, which is likely to be due to interactions
with PD-1 expressed on lymphocytes and dendritic cells [96]. [89Zr]Zr-nivolumab uptake
in tumours was histologically confirmed as PD-1+ T-cells and was predictive of response
to the nivolumab treatment. A competitive antagonist of PD-L1 has been radiolabelled
with copper-64 for imaging PD-L1 expression in mice: [64Cu]Cu-DOTA-HAC [100]. This
radiotracer was based on a soluble fragment of the PD-1 ectodomain: It exhibits a high
affinity for PD-L1 (110 pM), is small in size (14 kDa), and does not contain an Fc region,
thus avoiding the intrinsic limitation of antibodies as discussed above. A high tumour
uptake and favourable tumour-to-background ratios were observed at 1 h post-injection
of [64Cu]Cu-DOTA-HAC. The radiotracer was shown to be highly specific for human
PD-L1 and persisted in PD-L1+ tumours for at least 24 h. The rapid and specific uptake of
[64Cu]Cu-DOTA-HAC shows promise for further evaluation in clinical trials.
Table 3. Tracking therapeutic cell location and functional status using radiolabelled antibodies.
Target Radiopharmaceutical Imaging Reference Stage of Development
Cell Surface Markers
CD3 [89Zr]Zr-DFO-CD3
CD3 cell infiltration (after
anti-CTLA-4 treatment) [101,102] Preclinical
CD4 [89Zr]Zr-DFO-CD4
Whole body assessment of CD4
















T-cell receptor [90] Preclinical
Activation Markers
OX40 [64Cu]Cu-DOTA-AbOX40
Detection of T-cell activation to
predict tumour response to vaccine [105] Preclinical
ICOS [89Zr]Zr-DFO-ICOS
Noninvasive tracking of murine




Tumour-infiltrating NK cells and







Expression of CTLA-4 on
tumour-infiltrating lymphocytes [106] Preclinical
PD-1
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5. Conclusions and Perspectives
Imaging of cell-based cancer immunotherapies including genetically engineered cells
has found an important role in basic cancer research and is becoming a valuable tool
for the translation of new cell therapies into clinical settings. The ability to follow the
biodistribution of these cells in vivo provides important information on whether target
engagement has been successful, the intratumoural and intermetastatic heterogeneity of
therapeutic cell delivery, and how the cell uptake changes longitudinally. These data could
help predict and stratify which patients will respond to therapy as part of a personalised
treatment and could also be used to detect early response to therapy before changes
in tumour size are apparent. In this way, labelling a small percentage of the injected
therapeutic cell population could act as a companion biomarker for the larger proportion
of cells used for the treatment. Cell labelling methods have a wide range of applications in
addition to their use in oncology, and these approaches could be of great value for labelling
stem cells or other cell therapies in neurological and autoimmune diseases, as well as for
studying infectious diseases.
Imaging allows longitudinal tracking of therapeutic cells within a patient to be un-
dertaken non-invasively, as well as the detection of tumour heterogeneity, which is more
difficult with competing approaches such as tissue biopsy or liquid biomarkers. PET
affords a very high sensitivity for the detection of radiolabelled cells, and can report on cell
tracking at high spatial and temporal resolution. The spatial resolution of the radiolabel
within the tumour is limited by the fundamental PET resolution determined by the mean
distance travelled by a positron before annihilation, which varies with positron energy
and is isotope-specific, e.g., 0.6 mm for fluorine-18, 1.2 mm for zirconium-89, and 2.9 mm
for gallium-68 [107]. In practice, the achievable spatial resolution is lower and usually of
the order of several millimetres for most clinical PET applications. Temporal resolution
is limited by the number of counts acquired within a given time window to ensure that
the signal from the tumour or organ can be discriminated from background or noise. The
required temporal resolution for monitoring cell influx and efflux is of the order of hours
to days and is therefore not limited by the temporal resolution of the scanner, but rather by
the loss of signal due to either the isotope half-life or from label dilution due to cellular
proliferation for the direct cell labelling approaches. In practice, this is limited to 7–10 days
for long half-live radionuclides but could be extended in the future with the increased
sensitivity that will be afforded by total body PET systems [19].
The approaches to cell labelling described in this review provide complementary
information: Some assess the resident tumour immune populations, while others report on
the trafficking of cells in or out of the tumour. Direct ex vivo cell labelling specifically shows
the distribution of the injected labelled population and how it is taken up into the tumour
or organ of interest, with little or no background signal to complicate the analysis. A
potential complication of all cell labelling approaches, including direct cell labelling, is that
some of the labels could be released and may subsequently accumulate in adjacent cellular
subpopulations. Antibody or antibody fragment labelling is also highly specific, albeit for
a target rather than a cell population, so may label more than one resident cell population
and will demonstrate some non-specific background accumulation which may reduce the
sensitivity for detection. Antibody labelling also has the benefit of providing functional
information in addition to spatial localization and can inform on cellular activation status
and cell-cell interactions. Reporter genes are the most attractive approach given their
potential for a very high level of cellular specificity and since the target is not diluted with
cellular proliferation or tumour metastasis. The choice of reporter gene/target is based on
multiple factors: (a) The availability of specific tracers which ideally are suitable for PET
and clinically approved; (b) the background expression in tumours or normal organs, which
ideally is as low as possible; (c) favourable dosimetry to minimise concerns over radiation
exposure, and allow for measurement at multiple time points after administration of the
tagged cells; (d) limited or no biological effect deriving from expression of the transgene;
(e) alternatively, a transgene may be chosen to serve as a therapeutic effector or target for
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its application. The potential for non-human reporter genes to be immunogenic must also
be taken into consideration when addressing ideal system design, since this may affect
functionality and survival of transduced cells once injected into humans.
Two or more of these approaches could be combined using isotopes with different
half-lives to provide a multiparametric readout of both the resident immune cells, as well
as influx of cells from the circulation, i.e., a dual-isotope imaging approach. Alternatively, a
PET label could be incorporated into an experimental bifunctional probe, using MRI-based
approaches, for example, to probe more than one cellular population simultaneously or to
provide complementary simultaneous readouts as part of hybrid imaging with PET/MRI.
For clinical translation of PET cell labelling to be more widely used, significant tech-
nical and regulatory hurdles need to be overcome. SPECT cell labelling is already part of
clinical routine, and therefore good manufacturing practice (GMP) approaches and the
required infrastructure required for radiolabelling of cells already exists in many larger
institutions. The radiochemistry synthesis involved may have to be upscaled so that it
can be stably reproduced for routine large scale clinical use. CAR T-cell manufacturing
processes are well established and therefore the addition of PET labelling as a companion
biomarker for these therapies which already have obtained regulatory approval, would
require a change in practice and new approvals. As the PET label is found in trace quanti-
ties, most of the labelling approaches described here do not require additional toxicology
assessment when an established PET label is conjugated to human cells. However, if there
is a possibility of probe-target interaction resulting in deleterious effects on cell function
and viability, specific toxicology studies may be required in some instances.
The introduction of a transgene into live cells for human administration can raise
safety concerns and requires extensive regulatory scrutiny and validation before it can be
considered for clinical use to ensure long term stability and safety. In addition, preparation
of transduced cells for human injection is significantly more complicated and expensive
than the requirements for direct cell labelling procedures. Although reporter genes pose
significant challenges before being used routinely in a clinical setting, they present many
benefits when this can be achieved.
A key element in the translation of these techniques is clinical acceptance and evidence
of utility in a clinical setting. The imaging of cell therapies is a relatively new area and a
regulatory framework for more routine imaging studies remains to be defined. Most studies
to date have involved small numbers of patients from a single institution. Future larger
multisite studies are required to provide the evidence for both regulators and clinicians,
and it will be important to engage early with the pharmaceutical industry when designing
these studies. Repeatability and reproducibility are also key steps in the technical validation
stage of these studies. In the longer term, if cell labelling can be shown to better stratify
expensive cell therapies, then the imaging costs can be defrayed by reducing the use of
ineffective treatments or replacing them with more effective therapies at earlier timepoints.
This will provide evidence to deliver a change in clinical practice, and education and
training of both the imaging and oncological communities will facilitate this. In conclusion,
in vivo cell labelling using PET is a promising area for improving the understanding of
tumour biology, as well as addressing important clinical questions in the emerging field of
cell therapies.
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